Molecular Partners AG reported Q1 2026 financial results with CHF 79 million cash runway to late 2027 and clinical progress including MP0712 Phase 1/2a trial initiation and MP0317 Phase 2 study start.
Key takeaways
Cash and short-term deposits at CHF 79 million (USD 100 million) as of March 31, 2026, funding operations to late 2027.
Q1 2026 net loss of CHF 13.1 million, improved from CHF 16.8 million in Q1 2025.
MP0712 Phase 1/2a trial recruiting with four sites open, initial data expected 2026.
MP0317 Phase 2 study in cholangiocarcinoma initiated with eight sites activated.
MP0726 first-in-human imaging planned for H2 2026; new Radio-DARPin target nomination expected H2 2026.
All AGM proposals approved, including election of Clare Fisher to Board of Directors.